Candel Therapeutics Stock Analysis

CADL Stock  USD 4.64  0.03  0.65%   
Candel Therapeutics is undervalued with Real Value of 8.08 and Target Price of 18.5. The main objective of Candel Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Candel Therapeutics is worth, separate from its market price. There are two main types of Candel Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Candel Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Candel Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Candel Therapeutics was currently reported as 1.46. The company recorded a loss per share of 0.66. Candel Therapeutics had not issued any dividends in recent years. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company was incorporated in 2003 and is based in Needham, Massachusetts. Candel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. For more info on Candel Therapeutics please contact FOCIS MD at 617 916 5445 or go to https://www.candeltx.com.

Candel Therapeutics Investment Alerts

Candel Therapeutics generated a negative expected return over the last 90 days
Candel Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (55.18 M) with loss before overhead, payroll, taxes, and interest of (23.07 M).
Candel Therapeutics currently holds about 86.78 M in cash with (27.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0.
Candel Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 17.0% of the company shares are held by company insiders
Latest headline from globenewswire.com: Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

Candel Therapeutics Upcoming and Recent Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Candel Largest EPS Surprises

Earnings surprises can significantly impact Candel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-12
2021-09-30-0.29-0.260.0310 
2023-08-10
2023-06-30-0.3-0.34-0.0413 
2025-11-06
2025-09-30-0.1793-0.2262-0.046926 
View All Earnings Estimates

Candel Therapeutics Environmental, Social, and Governance (ESG) Scores

Candel Therapeutics' ESG score is a quantitative measure that evaluates Candel Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Candel Therapeutics' operations that may have significant financial implications and affect Candel Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Candel Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Northern Trust Corp2025-06-30
287.9 K
Tanager Wealth Management Llp2025-06-30
196.6 K
Renaissance Technologies Corp2025-06-30
163.6 K
Marshall Wace Asset Management Ltd2025-06-30
161.5 K
Charles Schwab Investment Management Inc2025-06-30
113.8 K
Morgan Stanley - Brokerage Accounts2025-06-30
113.7 K
Nuveen, Llc2025-06-30
92.5 K
Bank Of New York Mellon Corp2025-06-30
86.8 K
Wellington Management Company Llp2025-06-30
86.2 K
Fmr Inc2025-06-30
8.2 M
Blackrock Inc2025-06-30
2.3 M
Note, although Candel Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Candel Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 254.73 M.

Candel Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.52)(0.54)
Return On Capital Employed(0.48)(0.51)
Return On Assets(0.52)(0.54)
Return On Equity(0.83)(0.87)

Management Efficiency

Candel Therapeutics has return on total asset (ROA) of (0.4325) % which means that it has lost $0.4325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7017) %, meaning that it created substantial loss on money invested by shareholders. Candel Therapeutics' management efficiency ratios could be used to measure how well Candel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.54. The value of Return On Capital Employed is expected to slide to -0.51. At this time, Candel Therapeutics' Debt To Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0 this year, although the value of Total Current Assets will most likely fall to about 69.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 2.09  2.20 
Tangible Book Value Per Share 2.09  2.20 
Enterprise Value Over EBITDA(3.57)(3.74)
Price Book Value Ratio 4.15  4.35 
Enterprise Value Multiple(3.57)(3.74)
Price Fair Value 4.15  4.35 
Enterprise Value185.8 M195 M
Management at Candel Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta
(0.93)
Return On Assets
(0.43)
Return On Equity
(0.70)

Technical Drivers

As of the 17th of November 2025, Candel Therapeutics shows the Mean Deviation of 3.14, risk adjusted performance of (0.04), and Standard Deviation of 4.22. Candel Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Candel Therapeutics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Candel Therapeutics is priced correctly, providing market reflects its regular price of 4.64 per share. Given that Candel Therapeutics has information ratio of (0.09), we suggest you to validate Candel Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Candel Therapeutics Price Movement Analysis

java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Candel Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Candel Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Candel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Candel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Candel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Aguilar-cordova Estuardo over two weeks ago
Disposition of 16427 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.53 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over three months ago
Disposition of 10583 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 12.02 subject to Rule 16b-3
 
Nichols William Garrett over three months ago
Disposition of 937 shares by Nichols William Garrett of Candel Therapeutics at 1.29 subject to Rule 16b-3
 
Papa Joseph C over three months ago
Acquisition by Papa Joseph C of 14240 shares of Candel Therapeutics at 4.94 subject to Rule 16b-3
 
Radhakrishnan Maha over three months ago
Insider Trading
 
Aguilar-cordova Estuardo over six months ago
Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 5.23 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over six months ago
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.52 subject to Rule 16b-3
 
Tak Paul Peter over six months ago
Disposition of 400 shares by Tak Paul Peter of Candel Therapeutics at 9.0025 subject to Rule 16b-3
 
Charles Schoch over six months ago
Disposition of 5000 shares by Charles Schoch of Candel Therapeutics at 8.8338 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over six months ago
Disposition of 10582 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 12.02 subject to Rule 16b-3
 
Barone Francesca over six months ago
Acquisition by Barone Francesca of 115000 shares of Candel Therapeutics at 8.55 subject to Rule 16b-3
 
Aguilar-cordova Estuardo over six months ago
Disposition of 31335 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.61 subject to Rule 16b-3

Candel Therapeutics Outstanding Bonds

Candel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Candel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Candel bonds can be classified according to their maturity, which is the date when Candel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Candel Therapeutics Predictive Daily Indicators

Candel Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Candel Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Candel Therapeutics Forecast Models

Candel Therapeutics' time-series forecasting models are one of many Candel Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Candel Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Candel Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Candel Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Candel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Candel Therapeutics. By using and applying Candel Stock analysis, traders can create a robust methodology for identifying Candel entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(172.90)(181.55)
Operating Profit Margin(319.44)(335.41)
Net Loss(20.64)(21.67)
Gross Profit Margin(6.21)(6.52)

Current Candel Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Candel analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Candel analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
18.5Strong Buy3Odds
Candel Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Candel analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Candel stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Candel Therapeutics, talking to its executives and customers, or listening to Candel conference calls.
Candel Analyst Advice Details

Candel Stock Analysis Indicators

Candel Therapeutics stock analysis indicators help investors evaluate how Candel Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Candel Therapeutics shares will generate the highest return on investment. By understating and applying Candel Therapeutics stock analysis, traders can identify Candel Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow35.7 M
Long Term Debt2.6 M
Common Stock Shares Outstanding31.7 M
Total Stockholder Equity66.3 M
Total Cashflows From Investing Activities-16 K
Property Plant And Equipment Net2.7 M
Cash And Short Term Investments102.7 M
Cash102.7 M
Accounts Payable237 K
Net Debt-89.2 M
50 Day M A5.3185
Total Current Liabilities37.5 M
Other Operating Expenses33.4 M
Non Current Assets Total3.1 M
Forward Price Earnings43.4783
Non Currrent Assets Other329 K
Stock Based Compensation5.3 M
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.66)
Revenue Per Share
0.001
Return On Assets
(0.43)
Return On Equity
(0.70)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.